Literature DB >> 12925209

Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma.

Toshiyuki Yamamoto1, Kiyoshi Nishioka.   

Abstract

Systemic sclerosis is a connective tissue disease characterized by excessive deposition of extracellular matrix in the skin as well as various internal organs. Cellular infiltrates are found in the dermis in early systemic sclerosis, which are suggested to play an important part. Recent studies suggest the involvement of monocyte chemoattractant protein-1, a C-C chemokine, in the fibrotic process. This study examines the role of monocyte chemoattractant protein-1 in the induction of dermal sclerosis in a murine model of bleomycin-induced scleroderma. Immunohistochemical analysis showed that expression of monocyte chemoattractant protein-1 in the infiltrating mononuclear cells was enhanced at 2 to 3 wk following bleomycin treatment, whereas expression of monocyte chemoattractant protein-1 in fibroblasts was detected at later stages in the sclerotic skin. Reverse transcriptase-polymerase chain reaction analysis showed that monocyte chemoattractant protein-1 mRNA expression in the lesional skin peaked at 2 to 3 wk following bleomycin treatment. Expression of CCR-2, a major receptor for monocyte chemo-attractant protein-1, was also upregulated in the lesional skin at both protein and mRNA levels following bleomycin treatment. Administration of anti-monocyte chemoattractant protein-1 neutralizing antibody together with local bleomycin treatment reduced dermal sclerosis, along with a decrease of collagen content in the skin as well as mRNA expression of type I collagen. In vitro analysis showed that stimulation with monocyte chemoattractant protein-1 (10 ng per mL) upregulated alpha1(I) collagen and decorin mRNA expression in normal dermal fibroblasts, whereas mRNA levels of fibronectin and biglycan were not altered. These data suggest that monocyte chemoattractant protein-1 and CCR-2 signaling plays an important part in the pathogenesis of bleomycin-induced scleroderma. Monocyte chemoattractant protein-1 may contribute to the induction of dermal sclerosis via its direct effect of upregulation of mRNA expression of extracellular matrix on fibroblasts, as well as indirect effect mediated by a number of cytokines released from immunocytes recruited into the lesional skin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925209     DOI: 10.1046/j.1523-1747.2003.12408.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  21 in total

1.  Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma.

Authors:  M Kajii; C Suzuki; J Kashihara; F Kobayashi; Y Kubo; H Miyamoto; T Yuuki; T Yamamoto; T Nakae
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

Review 2.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

3.  Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.

Authors:  Minghua Wu; Mesias Pedroza; Robert Lafyatis; Anuh-Teresa George; Maureen D Mayes; Shervin Assassi; Filemon K Tan; Michael B Brenner; Sandeep K Agarwal
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

4.  Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

Authors:  Catherine Do; Viktor Drel; Chunyan Tan; Doug Lee; Brent Wagner
Journal:  J Invest Dermatol       Date:  2019-04-09       Impact factor: 8.551

5.  Immunohistochemical study of monocyte chemoattractant protein-1 in the pancreas of NOD mice following cyclophosphamide administration and during spontaneous diabetes.

Authors:  Yan Bai; Elizabeth Robinson; Ryan Chai; Jacqueline M Ross; Shiva Reddy
Journal:  J Mol Histol       Date:  2006-07-29       Impact factor: 2.611

6.  Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.

Authors:  Shervin Assassi; Xuan Wang; Guocai Chen; Ellen Goldmuntz; Lynette Keyes-Elstein; Jun Ying; Paul K Wallace; Jacob Turner; W Jim Zheng; Virginia Pascual; John Varga; Monique E Hinchcliff; Chiara Bellocchi; Peter McSweeney; Daniel E Furst; Richard A Nash; Leslie J Crofford; Beverly Welch; Ashley Pinckney; Maureen D Mayes; Keith M Sullivan
Journal:  Ann Rheum Dis       Date:  2019-08-07       Impact factor: 19.103

Review 7.  Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts?

Authors:  John Varga
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

8.  Elevated expression of isopeptide bond cross-links contributes to fibrosis in scleroderma and the healing wounds of tight skin mice.

Authors:  Janson C Sullivan; Donny D Kakati; Elliot Carter; Amy K Boyd; Themis R Kyriakides; Azin Agah
Journal:  Wound Repair Regen       Date:  2008 Sep-Oct       Impact factor: 3.617

Review 9.  In perspective: murine models of scleroderma.

Authors:  Minghua Wu; John Varga
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

10.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.